Market Overview

Aspire Capital Fund to Purchase Up to $20M of Cyclacel Common Stock for $6.29/Share

Related CYCC
The Week Ahead: Earnings, Earnings, And More Earnings
12 Biggest Mid-Day Losers For Friday
Cyclacel optimistic with subgroup of patients in failed late-stage study of sapacitabine; investors not on board, shares down 7% (Seeking Alpha)

Cyclacel Pharmaceuticals (NASDAQ: CYCC) (NASDAQ: CYCCP) today announced that it has entered into a common stock purchase agreement (the Purchase Agreement) with Aspire Capital Fund, LLC (Aspire). Aspire has committed to purchase up to $20 million of Cyclacel's common stock from time to time as directed by Cyclacel over the next two years at prices based on the market price at the time of each sale. Upon execution of the Purchase Agreement, Aspire invested $1 million in Cyclacel common stock at a per share price equal to the closing price of $6.29 on December 13, 2012 the date upon which the business terms were agreed to between Cyclacel and Aspire Capital.

"We are pleased to have entered into this agreement with Aspire who enjoys an excellent reputation as an investor," said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. "As we advance SEAMLESS, our Phase 3, registration-directed study, along with other clinical trials for sapacitabine, we plan to use the Aspire agreement

See full press release

Posted-In: News Guidance Asset Sales Management M&A Global


Related Articles (CYCC + CYCCP)

View Comments and Join the Discussion!

Partner Center